Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vinorebine, Everolimus · 1 trial · 2 indications
Progression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse or death.
| Arm | Type | Description |
|---|---|---|
| Vinorelbin and Everolimus | EXPERIMENTAL | - |
| standard therapy | OTHER | Vinorelbin |
| Name | Type | Description |
|---|---|---|
| Vinorebine, Everolimus | DRUG | Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress |
| Vinorelbine | DRUG | Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress |
Inclusion Criteria: 1 .Dated and signed patient informed consent before start of any in the protocol specified procedures 2. Histologically or cytologically confirmed Her2/neu negative, metastatic or locally advanced breast cancer, including inoperable local relapse, with measurable or non-measurab...
Vinorelbine, Everolimus is a combination of two small molecules being studied for the treatment of HER2-negative metastatic breast cancer and HER2-negative locally advanced breast cancer. It is currently in Phase 2 clinical development and is being investigated as a second-line treatment for advanced breast cancer.
The combination includes everolimus, an mTOR inhibitor, and vinorelbine, a chemotherapy agent. Everolimus targets mTOR, a protein involved in cell growth and proliferation, while vinorelbine disrupts microtubule dynamics to inhibit cancer cell division. The combination is being studied in biomarker-selected patients.
Vinorelbine, Everolimus is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate this combination therapy for the treatment of HER2-negative metastatic and locally advanced breast cancer.
Vinorelbine, Everolimus is in Phase 2 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities. One Phase 2 trial has been completed, involving 139 female participants aged 18 years and older.
Vinorelbine, Everolimus has one completed clinical trial, NCT01520103, which compared vinorelbine combined with the mTOR inhibitor everolimus versus vinorelbine monotherapy as second-line treatment in advanced breast cancer. The trial was conducted in Germany and enrolled 139 patients.
No, Vinorelbine, Everolimus is a combination of two drugs: vinorelbine and everolimus. Everolimus alone is an mTOR inhibitor, while vinorelbine is a chemotherapy agent. The combination is being studied to determine if adding everolimus to vinorelbine improves outcomes in HER2-negative advanced breast cancer.